Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Landscape assessment to characterize baseline access and multilevel barriers to IMProve Access to CAR-T CD19 therapy (IMPACT study) across Europe.

medRxiv : the preprint server for health sciences·2025
Same author

Reducing the Diagnostic Time for Childhood Cancer in Peru: A Hospital-Based Registry Analysis Four Years After Implementation of the Global Initiative for Childhood Cancer.

Pediatric blood & cancer·2025
Same author

Building Pediatric Hematology/Oncology Workforce Capacity in Latin America.

Pediatric blood & cancer·2025
Same author

Communication practices and information exchange for caregivers of children with cancer in Pakistan.

Frontiers in oncology·2025
Same author

Implementation of Comprehensive Surgical Guidelines for Hepatoblastoma: Analysis of the Children's Oncology Group AHEP0731 Phase III Trial.

Annals of surgery·2025

Related Experiment Video

Updated: Jul 14, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Reducing irinotecan-associated diarrhea in children.

Lars M Wagner1, Kristine R Crews, Clinton F Stewart

  • 1Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Lars.wagner@cchmc.org

Pediatric Blood & Cancer
|June 16, 2007
PubMed
Summary

Irinotecan, a cancer drug, can cause diarrhea in children. Cephalosporin prophylaxis may help prevent this side effect, allowing for higher irinotecan doses in pediatric cancer patients.

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Related Experiment Videos

Last Updated: Jul 14, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Area of Science:

  • Pediatric Oncology
  • Cancer Therapeutics
  • Pharmacology

Background:

  • Irinotecan is a vital chemotherapeutic agent increasingly used in pediatric oncology.
  • Diarrhea is a common and dose-limiting toxicity associated with protracted irinotecan administration in children.
  • Managing irinotecan-induced diarrhea is crucial for reducing patient morbidity and enabling higher, more effective treatment doses.

Purpose of the Study:

  • To review the pathogenesis and potential genetic factors contributing to irinotecan-induced diarrhea in pediatric patients.
  • To comprehensively summarize existing literature on prevention and treatment strategies for this significant toxicity.
  • To report on the feasibility and efficacy of cephalosporin prophylaxis in children receiving irinotecan.

Main Methods:

  • Comprehensive literature review of irinotecan toxicity, pathogenesis, and management strategies.
  • Analysis of data from 51 pediatric patients treated on various trials utilizing cephalosporin prophylaxis.
  • Evaluation of the safety and tolerability of cephalosporin prophylaxis in conjunction with irinotecan therapy.

Main Results:

  • The review synthesizes current knowledge on the mechanisms and genetic predispositions for irinotecan-related diarrhea.
  • Data from 51 pediatric patients indicate that cephalosporin prophylaxis is a feasible strategy.
  • This prophylactic approach allows for improved tolerance of higher doses of protracted irinotecan administration.

Conclusions:

  • Cephalosporin prophylaxis represents a viable option for mitigating irinotecan-induced diarrhea in pediatric cancer patients.
  • Implementing such strategies can enhance treatment adherence and potentially improve therapeutic outcomes.
  • Further research may solidify the role of prophylactic antibiotics in managing irinotecan toxicity in this population.